Industry Briefing
A single destination for timely, editor-curated robotics news from around the world.
Multiply Labs Secures $75 Million in Series B Funding for Robotic Drug Manufacturing Expansion
Multiply Labs has successfully raised $75 million in Series B funding aimed at enhancing its robotic manufacturing platform for cell and gene therapies, as well as advanced biologics. This funding round elevates the company's total funding to over $100 million since its inception in 2016. The significance of this funding lies in Multiply Labs' ability to address the challenges of manual biomanufacturing processes, which can lead to costly contamination and production delays. The company's robotic clusters are designed to integrate seamlessly with existing pharmaceutical equipment, promising a 74% reduction in cost per dose and up to 100 times the throughput compared to manual methods. Looking ahead, Multiply Labs plans to utilize the new capital to expand its manufacturing capabilities and accelerate product development. The company aims to transition from clinical-stage deployments to commercial-scale production, thereby increasing access to essential therapies for patients. No further timeline was disclosed at the time of publication.
AI AI Funding & Investment Robotics autonomous biologics drug discovery
AI’s Next Revolution: Multiply Labs Is Scaling Robotics-Driven Cell Therapy Biomanufacturing Labs
A startup is collaborating with prominent cell therapy companies to revolutionize the manufacturing process within clean rooms by integrating robotics technology. This innovative approach is set to significantly lower production costs by over 70% and enhance output efficiency compared to traditional manufacturing systems. The initiative aims to address the growing demand for cell therapies, which require precise and sterile environments for production. By leveraging advanced robotics, the startup is not only streamlining operations but also positioning itself as a key player in the rapidly evolving biotechnology sector. This development is particularly timely, as the industry seeks to meet increasing patient needs while maintaining high-quality standards in cell therapy manufacturing.
Robotics needs a service framework.
RSF defines a common language for robot service capability, lifecycle operations, certification pathways, and service-provider networks.
Join the RobotToday community on LinkedIn
Daily robotics news, in-depth analysis, conference highlights, and discussions with professionals worldwide.
